ONCOTHERAPY SCIENCE, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17 JPY | 0.00% |
|
-10.53% | -26.09% |
| Sales 2022 | 1.15B 7.23M | Sales 2023 | 1.13B 7.11M | Capitalization | 9.05B 56.81M |
|---|---|---|---|---|---|
| Net income 2022 | -2.57B -16.13M | Net income 2023 | -1.12B -7.01M | EV / Sales 2022 | 9.94 x |
| Net cash position 2022 | 1.84B 11.52M | Net cash position 2023 | 1.12B 7.01M | EV / Sales 2023 | 7 x |
| P/E ratio 2022 |
-5.03
x | P/E ratio 2023 |
-8.1
x | Employees | 60 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.45% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -10.53% | ||
| Current month | -15.00% | ||
| 1 month | -15.00% | ||
| 3 months | -19.05% | ||
| 6 months | -39.29% | ||
| Current year | -26.09% |
1 week
17.00
20.00
1 month
17.0021.00
Current year
17.0024.00
1 year
17.0045.00
3 years
17.00126.00
5 years
17.00229.00
10 years
17.00736.00
| Managers | Title | Age | Since |
|---|---|---|---|
Junichi Shimada
PSD | President | 62 | 21-11-30 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 17-06-30 |
Yuichi Komine
BRD | Director/Board Member | 52 | 08-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yuichi Komine
BRD | Director/Board Member | 52 | 08-05-31 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 17-06-30 |
Hatsuo Kato
CHM | Chairman | 80 | 20-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 17 | -5.56% | 5,666,000 |
| 24-04-25 | 18 | -5.26% | 3,194,200 |
| 24-04-24 | 19 | 0.00% | 2,604,900 |
| 24-04-23 | 19 | 0.00% | 2,248,500 |
| 24-04-22 | 19 | 0.00% | 3,319,200 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.
Calendar
2024-08-01
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.09% | 23.5M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 4564 Stock
